Ensayos clínicos

8.676 ensayos encontrados

ReclutandoClinicalTrials.gov

An International Observational Study of Adults With Acute Infection

OBSERVATIONALInicio: 25 de ago de 2025ID: NCT07069400

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event

INTERVENTIONALInicio: 2 de sept de 2025ID: NCT07157774

ReclutandoFase 2ClinicalTrials.gov

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

INTERVENTIONALInicio: 3 de jul de 2025ID: NCT06863272

ReclutandoClinicalTrials.gov

Fabry Disease Registry Protocol

OBSERVATIONALInicio: 31 de jul de 2001ID: NCT00196742

ReclutandoFase 3ClinicalTrials.gov

Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

INTERVENTIONALInicio: 27 de sept de 2024ID: NCT06492616

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, 2-arm, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

INTERVENTIONALInicio: 6 de ago de 2025ID: NCT07088068

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations

INTERVENTIONALInicio: 18 de abr de 2024ID: NCT06319820

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

INTERVENTIONALInicio: 19 de ago de 2024ID: NCT06461897

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

INTERVENTIONALInicio: 27 de ene de 2025ID: NCT06717347

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

INTERVENTIONALInicio: 15 de feb de 2024ID: NCT06230224

ReclutandoFase 2ClinicalTrials.gov

A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression

INTERVENTIONALInicio: 18 de jul de 2025ID: NCT06926660

ReclutandoFase 2ClinicalTrials.gov

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study

INTERVENTIONALInicio: 10 de nov de 2021ID: NCT05039840

ReclutandoFase 3ClinicalTrials.gov

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

INTERVENTIONALInicio: 11 de jul de 2023ID: NCT05980949

ReclutandoFase 3ClinicalTrials.gov

An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies

INTERVENTIONALInicio: 20 de oct de 2020ID: NCT04464226

ReclutandoFase 3ClinicalTrials.gov

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

INTERVENTIONALInicio: 24 de jul de 2025ID: NCT06757634

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

INTERVENTIONALInicio: 5 de abr de 2019ID: NCT03773965

ReclutandoFase 3ClinicalTrials.gov

A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-(Milligram) mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms

INTERVENTIONALInicio: 25 de jul de 2024ID: NCT06559306

ReclutandoClinicalTrials.gov

Observational Study, for Quality Assessment, of Sarcoma As a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK

OBSERVATIONALInicio: 30 de jun de 2019ID: NCT04181970

ReclutandoFase 3ClinicalTrials.gov

A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

INTERVENTIONALInicio: 10 de may de 2021ID: NCT04862663

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

INTERVENTIONALInicio: 30 de jun de 2025ID: NCT06966700